Cardinal Health issued fiscal 2027 EPS guidance of $12.40 to $12.60, implying 13% to 15% growth off a normalized baseline.
Previously announced specialty distribution wins are ramping and are expected to benefit the Pharma segment in fiscal 2027.
BioPharma Solutions secured two additional gene therapy commercialization agreements, supporting therapies expected to enter the market in fiscal 2028.
Strive Medical and AdaptHealth's Diabetes Health tuck-in acquisitions are expected to contribute 2% to Other segment profit growth in fiscal 2027.
Nuclear and Precision Health Solutions is guided for double-digit Theranostics growth in fiscal 2027 while expanding PET capacity.
Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for Cardinal Health, Inc. and 4,900+ companies.